Growing evidence supports a major role for ATX, the enzyme responsible for the production of extracellular LPA, in inflammatory conditions, cancer and pulmonary fibrosis [5, 8], rendering it a promising therapeutic target. This evidence concerns the gene ENPP2 and pulmonary fibrosis.